Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | Chief Business Officer | February 10, 2020 | February 12, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date February 10, 2020 · Filed February 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.28 · Expires 2030-02-09 | Direct | 50,000 |
Reported balance
After 2020-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-10 · Grant · Acquired 50,000 · Balance 50,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2020 Filed Feb 12, 2020 17:12 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0000899243-20-004313 · doc4.xml · derivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-09 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2020. Read SEC document |
| December 24, 2019 Filed Dec 26, 2019 16:12 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 4,463 | $16.01 | $71,452.63 |
DisclosureSEC source: 0001562180-19-006266 · primarydocument.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,786 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 10:12 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 9,867 | $16.03 | $158,168.01 |
DisclosureSEC source: 0001562180-19-006260 · primarydocument.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,249 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:02 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 5,415 | $16.07 | $87,019.05 |
DisclosureSEC source: 0001562180-19-003624 · primarydocument.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,116 F1 · kind: This trade is pursuant to an active 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.00 to $16.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 05, 2019 Filed Feb 7, 2019 16:16 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000899243-19-002865 · doc4.xml · derivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-02-04 F1 · derivative.exercise_date: This option shall vest and become exercisable in 12 equal quarterly installments beginning on January 1, 2019. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries B Preferred Stock · Derivative | 857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · derivative · entry 3 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionSeries A Preferred Stock · Derivative | 6,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · derivative · entry 2 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,581 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
| June 25, 2018 Filed Jun 27, 2018 16:30 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | ConversionCommon Stock | 2,912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-018331 · doc4.xml · nonDerivative · entry 1 ISACSON CHRISTINA K. · CIK 0001741281 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a 2.58398:1 basis upon the closing of the Issuer's initial public offering on June 25, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.